Holy Evolution Pharma

Holy Evolution (Shanghai) Biotechnology is a China-based biotech company specializing in the directed evolution and engineering of proteins for therapeutic use. The company leverages a proprietary high-throughput platform that integrates molecular biology with advanced screening technologies to accelerate the discovery of optimized protein drugs. Their primary research and development efforts are concentrated on metabolic disorders, including obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). By evolving proteins to exhibit superior pharmacological properties, Holy Evolution aims to create next-generation biologics that surpass the efficacy and safety profiles of existing treatments. The firm has successfully raised significant venture capital from top-tier investors such as Matrix Partners China, GL Ventures, and Qiming Venture Partners. Headquartered in Shanghai, the company is positioned as a leader in the application of synthetic biology for drug discovery within the Chinese ecosystem.